37 results about "Secondary osteoporosis" patented technology

A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.

The invention relates to a medicinal composition containing strontium salts and vitamin D derivatives. Mixed with auxiliary materials acceptable on pharmacy, the medicinal composition of the invention can be prepared into oral formulations such as particulate granules, common tablets, chewable tablets, dispersible tablets, orally disintegrating tablets, effervescent tablets, buccal tablets, capsules, softgels, sustained release tablets, sustained release capsules, oral solutions, syrups, etc., and can be used to prevent and treat various primary or secondary osteoporosis.

Compositions and methods for the treatment of osteoporosis and/or inflammatory joint disease are provided herein. The compositions contain a folate, such as a reduced folate, and folic acid. The folate is preferably 5-methyltetrahydrofolate, and most preferably 5-methyl-(6S)-tetrahydrofolic acid. The folate and folic acid can be given in the same dosage unit or separate dosage units, and more than one dosage unit can be given per dose. The compositions may also contain one or more vitamins and minerals selected from vitamin B12, vitamin B6, vitamin D3, calcium, magnesium, and polyunsaturated fatty acids (PUFAs). These ingredients are optional, but preferable (especially the vitamins and minerals). The compositions may further contain one or more additional ingredients such as vitamins, minerals, and laxatives. The compositions are useful in the treatment of all forms of osteoporosis, including primary osteoporosis and secondary osteoporosis, and/or inflammatory joint diseases, especially in patients having a folic acid metabolism deficiency. The compositions are particularly useful in the treatment of inflammatory joint diseases, with complications that include bone loss, fracture, and osteoporosis. In addition, the compositions are beneficial for the prevention of osteoporosis in subjects who do not yet have the disease, but who are at risk for getting osteoporosis, such as post-menopausal women, subjects with osteopenia (mid thinning of the bone mass), subjects with an inflammatory joint disease, or people who are over the age of 70.

The invention discloses application of a compound traditional Chinese medicine to prevention and treatment of an osteoporosis disease, belonging to new application of the traditional Chinese medicine. The compound traditional Chinese medicine is prepared from the following Chinese medicinal herbs in percentage by weight: 15-35 percent of glossy privet fruit, 10-25 percent of Japanese thistle herbor root, 5-20 percent of largehead atractylodes rhizome, 5-20 percent of root of red-rooted salvia, 5-15 percent of coptis root, 5-15 percent of pseudo-ginseng root, 5-15 percent of eucommia and 5-15percent of fingered citron. As proved by an experiment, the compound traditional Chinese medicine has remarkable treatment effects on the prevention and treatment of primary osteoporosis, secondary osteoporosis, osteoporosis caused by hyperlipidaemia or an osteoporosis disease caused by glucose metabolism syndrome, definite clinical curative effect and no remarkable side effect according to observation.

The invention discloses probiotics and application thereof in secondary osteoporosis, and belongs to the technical field of microorganisms. The lactobacillus plantarum HFY15 is lactic acid bacteria (LAB) with the preservation number of CGMCC No. 16648, and the Lactobacillus plantarum HFY15 is separated and identified from natural yak yoghourt. A rat secondary osteoporosis (OP) model is establishedby using retinoic acid, and prevention effect of the ahfy15 on the OP is researched; the results show that the supplement of the HFY15 increases the expression of osteogenic marker genes, inhibits the expression of osteoclast genes, and stimulates the formation of bones; and a research result provides a new effective strategy for prevention and treatment of OP.

The present invention provides a multi-component kit comprising a therapeutically effective amount of a bisphosphonate or analogue thereof in combination with an effective amount of Vitamin D, a metabolite thereof, a precursor thereof or an analogue thereof, wherein the kit provides instructions for daily dosing and correct chronological order of administration of components to provide a dosing regime for reducing secondary osteoporotic skeletal fractures in subjects at risk for vitamin D deficiency.

The invention mainly relates to a cancellous bone-benefiting prescription for treating osteoporosis and a preparation technology of the cancellous bone-benefiting prescription. The cancellous bone-benefiting prescription comprises the following active ingredients in parts by weight: 25-35 parts of astragalus membranaceus, 13-17 parts of codonopsis pilosula, 10-14 parts of angelica sinensis, 14-16 parts of eucommia ulmoides, 14-16 parts of epimedium brevicornum maxim, 9-11 parts of rhizoma corydalis, 9-11 parts of myrrh and 16-20 parts of caulis spatholobi. The cancellous bone-benefiting prescription has the effects of tonifying kidney and spleen, nourishing the blood and promoting blood circulation, strengthening tendons and bones, and activating meridians to stop pain, can effectively treat primary and secondary osteoporosis, and has significant curative effects on back and loin aching, tiredness and dull pain, waist tenesmus, limbs lassitude and numbness, tiredness and weakness, dizziness, legs and feet cramp and the like due to spleen and kidney deficiency and blood stasis. The preparation technology is simple, and the production cost is low. In the preparation technology, one half of astragalus membranaceus and one half of codonopsis pilosula are decocted with the epimedium brevicornum maxim, the rhizoma corydalis and the caulis spatholobi, the other half of astragalus membranaceus and the other half of codonopsis pilosula as well as the angelica sinensis, the eucommia ulmoides and the myrrh are made into powder. Therefore, the effects of the prepared cancellous bone-benefiting prescription are significant. The cancellous bone-benefiting prescription and the preparation technology thereof are suitable for popularization and application.

The invention discloses a new purpose of N-(2)-L-alanyl-L-glutamine. The new purpose is characterized in that the purpose is an application of the N-(2)-L-alanyl-L-glutamine or the pharmaceuticaly-acceptable salt, ester and solvate to preparation of medicines for resisting osteoporosis. Through in vivo experiment, the inventor finds that the N-(2)-L-alanyl-L-glutamine can reduce the length of thigh bones, increase the diameter of the thigh bones and reduce the indexes of blood calcium concentration and the like. The new purpose of the N-(2)-L-alanyl-L-glutamine has the advantages that medicines can be applied to treatment for resisting osteoporosis, and have treatment protective effects on primary osteoporosis, secondary osteoporosis and idiopathic osteoporosis.

The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, facture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.

An application of nano (0.1-1000 nm) copper powder in preparing the medicines to prevent and treat osteoporosis and bone fracture is disclosed. Its advantages are sure curative effect and low toxic by-effect.

The invention mainly relates to a cancellous bone-invigorating formula for treating osteoporosis and a preparation technology thereof. The formula comprises the following raw materials by weight: 12-18 parts of radix rehmanniae praeparata, 13-17 parts of cornus officinalis, 10-14 parts of angelica sinensis, 14-16 parts of epimedium brevicornum maxim, 10-14 parts of semen cuscutae, 10-14 parts of medlar, 11-13 parts of rhizoma atractylodis macrocephalae and 11-13 parts of lumbricus. The cancellous bone-invigorating formula can treat the primary and secondary osteoporosis and osteomalacia effectively, takes significant curative effects on symptoms such as back, waist or whole body aching and tired, limb weakness, legs and feet cramp, deadlimb, dysphoria and irritability, palpitation and insomnia, sweating, a reddened tongue, yellowish coated tongue, a yellowish coatedtongue with crack and thready rapid pulse and the like due to deficiency of kidney-yin and blood stasis, and achieves remarkable effects of preventing bone mineral density from being reduced, reducing the bone turnover, and improving the balanced capacity. According to the invention, the preparation technology is simple, the production cost is low, and the curative effect of the drug prepared according to the formula is remarkable. Therefore, the formula and the preparation technology thereof are suitable for popularization and application.

Compositions and methods for the prevention and treatment of osteoporosis are provided herein. The compositions contain one or more isoflavones, such as genistein and derivatives thereof, in combination with one or more folates, such as a reduced folate and/or folic acid; and/or one or more polyunsaturated fatty acids (PUFAs), such as an omega-3 and/or omega-6 fatty acid. The isoflavones, folates and/or essential fatty acid may be administered together or in separate dosage units. The compositions may optionally contain other vitamins, minerals, and ingredients, such as, emollient laxatives. The compositions are useful in the treatment of all forms of osteoporosis, including primary osteoporosis and secondary osteoporosis, and/or inflammatory joint diseases, especially in patients having a folic acid metabolism deficiency. The compositions are particularly useful in the treatment of inflammatory joint diseases, with complications that include bone loss, fracture, and osteoporosis. In addition, the compositions are beneficial for the prevention of osteoporosis in subjects who do not yet have the disease, but who are at risk for getting osteoporosis, such as post-menopausal women, subjects with osteopenia (mid thinning of the bone mass), subjects with an inflammatory joint disease, or people who are over the age of 70.

The invention discloses an application of incadronate disodium in preparing drugs for preventing and treating osteoporosis. An animal experiment research finds that the incadronate disodium not only has good preventive and therapeutic effects on osteoporosis in an oophorectomized rat, but also can remarkably increase the bone density and bone calcium content of the rat suffers from retinoic acid-induced osteoporosis. The incadronate disodium can be prepared into any clinically-acceptable oral preparations such as tablet, capsule, granule, suspension and oral liquid for treating primary and secondary osteoporosis and fracture caused by osteoporosis.

The invention relates to a formula and a production process of energy metabolism improving healthcare foods and medicines consisting of fructose and radix salviae miltiorrhizae. The invention discloses an energy mixture composed of fructose and radix salviae miltiorrhizae, in particular the energy mixture consisting of 12 g of crystalline fructose per 100 g of the crude drug extract of Salvia miltiorrhiza, allowing that the fructose can play a better role in providing energy and protecting heart, liver and bone together with Radix Salviae Miltiorrhizae. The mixture especially has obvious curative effect on senile osteoporosis and secondary osteoporosis caused by glucocorticoids and other drugs or diseases, and also has good health care effect on diabetes, coronary heart disease and other aging-related diseases. The invention discloses formulas and production processes of capsules, granules, injections, oral liquid, beverages and bagged tea which can be supplied for clinic use and are prepared by from fructose and salvia miltiorrhiza according to the proportion of the fructose and salvia miltiorrhiza.

The invention relates to a purpose and relevant medicine of a ZEB1 (Zinc Finger E-Box-Binding Protein 1) gene, and particularly relates to application of the ZEB1 gene to preparation of medicine for preventing and/or treating osteoporosis diseases, in particular to application of a ZEB1 gene lipidosome to preparation of medicine for preventing and/or treating osteoporosis diseases, so that the exogenous ZEB1 gene can be efficiently and specifically expressed in bone blood vessel endothelial cells. The ZEB1 gene lipidosome provided by the invention can obviously promote bone angiogenesis and promote osteogenesis. The effects on primary osteoporosis and secondary osteoporosis are obvious, and an obvious treatment effect is particularly achieved on postmenopausal osteoporosis. The ZEB1 gene provided by the invention can activate a Notch/Dll4 channel and can promote bone angiogenesis and osteogenesis, so that the bone loss is finally reduced; the osteoporosis process is inhibited; and theZEB1 gene lipidosome has low toxicity and is suitable for being further developed into gene medicine or medicine targets for preventing or treating osteoporosis.

The present invention relates to a formulation of Spinacea oleracea useful for the prevention or treatment of osteo-health related disorders. The present invention relates to the field of pharmaceutical formulation that provides extract, fractions, pure compound isolated from natural sources and formulation thereof useful for the prevention and treatment of various medical indications. Further, this invention relates to conditions associated with estrogen dependent or independent diseases (primary/secondary osteoporosis) or syndromes or disorders preferably relating to cartilage such as osteoarthritis caused in humans and animals. Furthermore, this invention relates to achievement of peak bone mass during skeletal growth and health in humans and animals. Particularly, the present invention relates to the processes for the preparation of biologically active extracts, from Spinacea oleracea from the family Amaranthaceae their pharmaceutically acceptable excepients and compositions of the principal aspect of the present invention.

The present invention provides a composition for preventing or improving human osteoporosis, comprising molecular hydrogen as an active ingredient. More specifically, the present invention provides a composition for preventing or improving human osteoporosis, wherein the human osteoporosis is primary osteoporosis and/or secondary osteoporosis.

The invention relates to a composition for preventing and/or treating osteoporosis, which is characterized by comprising the following components in parts by weight: 15-150 parts of radix achyranthis bidentatae, 1-60 parts of quinoa and 1-60 parts of white mulberry leaf. The invention also provides application of the composition in preparation of medicines for preventing and/or treating osteoporosis. The osteoporosis disclosed by the invention comprises primary osteoporosis and secondary osteoporosis. The composition disclosed by the invention is remarkable in drug effect, simple in preparation method and suitable for various preparation types.